@CKD_ce retweeted
8/8: Click on this video for a full summary of the trial results!
#SponsoredbyCleerly
@CKD_ce retweeted
7/8: In #PARAMOUNT, plaque-based care produced a win ratio of 2.0 versus usual care for the prespecified hierarchical composite. The difference was driven primarily by greater diagnostic certainty and lower LDL-C, important context when interpreting the overall trial result.
@CKD_ce retweeted
5/8: A #WinRatio of 1.0 ➡️no advantage for either arm. WR 1.2 ➡️test treatment has 20% more wins than losses; 1.5 ➡️test treatment has 50% more wins than losses; 2.0 ➡️test treatment has twice as many wins as losses. In #PARAMOUNT, WR = 2.0
@CKD_ce retweeted
4/8: #WinRatio allows a clinical trial to assess several different measures of treatment benefit simultaneously, without treating all outcomes as equally important. The win ratio is the number of comparisons won by the experimental treatment divided by the number lost.
@CKD_ce retweeted
3/8: A hierarchical #WinRatio was calculated for each plaque-based care patient vs each usual care patient for 4 outcomes, ranked by clinical priority:
@CKD_ce retweeted
1/8: The #PARAMOUNT trial of #coronary plaque-based care was presented this morning at #AHA26. Here are the key findings and some context for interpreting the results. The trial and this post were sponsored by @CleerlyHealth, for whom I serve as a consultant.
@CKD_ce retweeted
8/8: Click on this video for a full summary of the trial results!
#SponsoredbyCleerly
@CKD_ce retweeted
5/8: A #WinRatio of 1.0 ➡️no advantage for either arm. WR 1.2 ➡️test treatment has 20% more wins than losses; 1.5 ➡️test treatment has 50% more wins than losses; 2.0 ➡️test treatment has twice as many wins as losses. In #PARAMOUNT, WR = 2.0
@CKD_ce retweeted
4/8: #WinRatio allows a clinical trial to assess several different measures of treatment benefit simultaneously, without treating all outcomes as equally important. The win ratio is the number of comparisons won by the experimental treatment divided by the number lost.
@CKD_ce retweeted
3/8: A hierarchical #WinRatio was calculated for each plaque-based care patient vs each usual care patient for 4 outcomes, ranked by clinical priority:
@CKD_ce retweeted
1/8: I am pleased to share with you the top-line results from the #PARAMOUNT trial of #coronary #plaque-based care that were presented this morning at #AHA26! The trial was supported by @Cleerlyhealth, to which I am a consultant. Here are the essentials:
@CKD_ce retweeted
11b) . . . the first Ph 3 results for #enlicitide, the leading candidate oral #PSCK9i, shown in early trials to ⬇️LDL by as much as 60%. PR just after ESC ➡️at AHA we'll see positive LLT results on that drug in the #CORALreef program. #LBCTs are scheduled to be presented.
Replying to @onc_ce @harrisoncn1
42) Congratulations! You are up to date from #EHA26 on advances in therapy for #anemia associated with #myelofibrosis, AND you also just earned 1 hour of 🆓CE/#CME credit! Claim your certificate now at oncologytweetorials-ce.com/m….
Many thanks to our 🏆expert faculty @harrisoncn1!
22b) Duration of these responses, as well as the reduction in TB ≥ 50% with ≥ 4 units, was longer with #luspatercept compared with placebo
























